A supplemental application for Filspari (sparsentan) for efficacy was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2025. This approval pertains to NDA 216403 S-5, indicating an update to the drug's existing approval.
Background
Filspari (sparsentan) is a medication sponsored by TRAVERE. The FDA previously approved Filspari, and this supplemental application for efficacy represents an update to the drug's existing approval. Supplemental applications are common mechanisms for drug manufacturers to submit new information to the FDA, which can include new indications, changes in dosage or administration, or, as in this case, additional data supporting the drug's efficacy.
What this means
The FDA's approval of this supplemental application for Filspari (sparsentan) for efficacy signifies an important update to its prescribing information. A supplemental application for efficacy typically indicates that new data has been submitted and reviewed by the FDA, either expanding on existing efficacy claims, refining the target patient population, or providing further evidence for the drug's effectiveness in a previously approved indication. For clinicians, this means updated information will be available in the drug's official label, potentially influencing prescribing decisions or patient selection based on the new efficacy data.
Source
The information regarding the supplemental approval for Filspari (sparsentan) was sourced from the U.S. Food and Drug Administration (FDA). This approval, identified as NDA 216403 S-5, was recorded on August 27, 2025, and is accessible via accessdata.fda.gov.